News

Main Page > News > bioGenous News
bioGenous Participates in the BioCon China Expo 2022
Publication Date:2022-09-09

 

On September 8, 2022, the three-day BioCon Expo 2022 successfully concluded at the Hangzhou International Expo Center!

 

With the rapid development of China's biopharmaceutical industry, this year's event, themed "Foreseeing the New World of Biopharmaceuticals," showcased forward-thinking and innovative technologies and services across 10,000+ square meters of exhibition space. More than 200 renowned exhibitors from the biopharmaceutical field participated, attracting over 10,000 industry professionals and creating a grand "feast" for the industry.

 

As a leading one-stop provider of organoid technology products and solutions, bioGenous actively participated in the exhibition, engaging with experts and professionals in the industry to share insights and innovations.

 

bioGenous' technical experts engaged in on-site discussions with visiting professionals, addressing questions related to organoid products and the challenges in organoid technology. They provided comprehensive product and technical consultation services, receiving widespread acclaim.

 

In the peak of summer, by the banks of the Qiantang River, bioGenous welcomed this grand gathering of experts and scholars. We look forward to meeting you all again and wish everyone a happy Mid-Autumn Festival.

-

 

Scan the QR code to add our assistant on WeChat

Join the 「类器官技术交流群」

Get the "Primary Tumor Organoid Culture" protocol and operation video.

 

 

-

 

bioGenous is dedicated to providing standardized, modular organoid products and technical support for biomedical research, drug development, and clinical precision medicine. The company has already served over 200 pharmaceutical development companies, top-tier hospitals, and research institutions, offering solutions that include organoid automation equipment, multi-tissue whole-process reagent kits, organoid culture and biobank construction technologies, and organoid-based drug development and precision medicine subsystems. With internationally leading organoid technology and proprietary intellectual property, bioGenous is positioning itself as an upstream unicorn in the industry, driving a revolution in multi-domain biomedical modeling.

 

 

Tel : 400-600-8315

Web : www.biogenous.cn

E-mail : info@biogenous.cn

分享到微信